PFG Investments LLC Purchases Shares of 21,880 Cassava Sciences, Inc. (NASDAQ:SAVA)

PFG Investments LLC purchased a new stake in shares of Cassava Sciences, Inc. (NASDAQ:SAVA) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,880 shares of the company’s stock, valued at approximately $444,000. PFG Investments LLC owned 0.05% of Cassava Sciences at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Montag A & Associates Inc. boosted its holdings in Cassava Sciences by 50.0% during the third quarter. Montag A & Associates Inc. now owns 1,500 shares of the company’s stock valued at $25,000 after acquiring an additional 500 shares during the period. Teacher Retirement System of Texas boosted its holdings in Cassava Sciences by 4.7% during the third quarter. Teacher Retirement System of Texas now owns 11,269 shares of the company’s stock valued at $188,000 after acquiring an additional 509 shares during the period. Raymond James & Associates boosted its holdings in Cassava Sciences by 0.8% during the fourth quarter. Raymond James & Associates now owns 74,097 shares of the company’s stock valued at $1,668,000 after acquiring an additional 565 shares during the period. NBC Securities Inc. boosted its holdings in Cassava Sciences by 9.3% during the first quarter. NBC Securities Inc. now owns 7,650 shares of the company’s stock valued at $155,000 after acquiring an additional 650 shares during the period. Finally, Swiss National Bank lifted its stake in shares of Cassava Sciences by 0.9% in the third quarter. Swiss National Bank now owns 87,200 shares of the company’s stock valued at $1,451,000 after buying an additional 800 shares during the period. 38.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $124.00 target price on shares of Cassava Sciences in a research note on Tuesday, March 5th.

Cassava Sciences Price Performance

Shares of NASDAQ SAVA traded down $0.15 during mid-day trading on Tuesday, hitting $22.15. The company had a trading volume of 812,690 shares, compared to its average volume of 771,559. The business’s 50-day simple moving average is $21.38 and its 200-day simple moving average is $20.27. Cassava Sciences, Inc. has a 12 month low of $12.32 and a 12 month high of $32.10. The firm has a market cap of $957.99 million, a P/E ratio of -9.55 and a beta of -0.45.

Cassava Sciences (NASDAQ:SAVA) last released its earnings results on Wednesday, February 28th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.10). As a group, sell-side analysts predict that Cassava Sciences, Inc. will post -2.01 EPS for the current year.

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.